Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13217488 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL3198143 | 0.84 | KDM4E (0.36) | KDM4EALDH1A1HSD17B10HPGDNPSR1 | |
| SCHEMBL2956803 | 0.80 | ALDH1A1 (0.37) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL3196117 | 0.72 | KDM4E (0.34) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL6409214 | 0.71 | ALDH1A1 (0.34) | KDM4EALDH1A1HPGDMAPTL3MBTL1 | |
| SCHEMBL4245735 | 0.70 | NPSR1 (0.39) | MAPTNPSR1POLB | |
| SCHEMBL8278554 | 0.69 | ALDH1A1 (0.41) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL24553235 | 0.68 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4813254 | 0.68 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL13217093 | 0.67 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | KDM4E 4327/4885ALDH1A1 1186/4885HSD17B10 3580/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | KDM4E 3658/4885ALDH1A1 1467/4885HSD17B10 3794/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | KDM4E 1159/4885ALDH1A1 3230/4885HSD17B10 1746/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | KDM4E 2115/4885ALDH1A1 686/4885HSD17B10 2805/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | KDM4E 2115/4885ALDH1A1 686/4885HSD17B10 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.